

## Custom G4 Microarrays Can Determine a Large-Scale Ligand Binding Selectivity

**Track Code:** 2020-YANG-69054

**Categories:**

- Chemistry and Chemical Analysis
- Pharmaceuticals

**Keywords:**

- Arrays
- Cancer Drug
- Chemistry and Chemical Analysis
- DNA
- Drug Development
- high throughput
- Medicinal Chemistry
- Micro-Array
- Molecular Biology
- Molecular Chemistry
- Molecule Reactions
- Pharmaceuticals

Researchers at Purdue University have developed new custom G-quadruplex (G4) microarrays for determining ligand-binding selectivity of potential drugs on a large-scale. The G4 is a novel secondary structure of DNA that are formed in guanine-rich genomic regions and have potential as drug targets. G4s are especially important drug targets because they provide a means of addressing otherwise undruggable targets. As one example, MYC is an important oncogene that is not amenable to targeting by traditional drug design; however, its regulation involves a G4 that is a potential drug target. Purdue researchers have created a high-throughput unbiased microarray platform to observe binding affinity and selectivity of drugs targeted to G4s like the G4 involved in MYC regulation. In testing, the new microarray was able to systematically assess binding of proteins, small molecules, and antibodies in more than 25,000 potential G4 sequences.

**Advantages:**

- High-Throughput
- Unbiased
- Accurate

**Potential Applications:**

-Drug Discovery  
-Cancer Treatment

**Technology Validation:**

The microarray has been tested with proteins, small molecules, and antibodies against more than 25,000 potential G4 sequences.

**Recent Publication:**

"Custom DNA Microarrays Reveal Diverse Binding Preferences of Proteins and Small Molecules to Thousands of G-Quadruplexes"

Journal of American Chemical Society Chemical Biology

DOI: 10.1021/acscchembio.9b00934

**People:**

- Yang, Danzhou (Project leader)
- Vinson, Charles
- Wu, Guanhui

**Intellectual Property:**

**Application Date:** April 27, 2021

**Type:** Utility-Gov. Funding

**Country of Filing:** United States

**Patent Number:** (None)

**Issue Date:** (None)

**Application Date:** April 28, 2020

**Type:** Provisional-Gov. Funding

**Country of Filing:** United States

**Patent Number:** (None)

**Issue Date:** (None)

**Contact OTC:**

Purdue Office of Technology Commercialization

The Convergence Center

101 Foundry Drive, Suite 2500

West Lafayette, IN 47906

Phone: (765) 588-3475

Fax: (765) 463-3486

Email: [otcip@prf.org](mailto:otcip@prf.org)